RESUMO
Isolation rates of Candida glabrata at ≤2 days were 8.9% and 34.8% at >2 days; for Cryptococcus neoformans, they were 0.9% and 8.6%, respectively (1741 fungemia analyzed). An incubation time >2 days supports candins as presumptive treatment for C. glabrata, keeping in mind the risk of Cryptococcus fungemia.
Assuntos
Antifúngicos/uso terapêutico , Candida glabrata/isolamento & purificação , Cryptococcus neoformans/isolamento & purificação , Fungemia/diagnóstico , Fungemia/tratamento farmacológico , Humanos , Fatores de TempoRESUMO
OBJECTIVE: To assess the safety and immunogenicity of live attenuated yellow fever (YF) 17D vaccine in adults receiving systemic corticosteroid therapy. METHODS: All adult travelers on systemic corticosteroid therapy who had received the YF17D vaccine in 24 French vaccination centers were prospectively enrolled and matched with healthy controls (1:2) on age and history of YF17D immunization. Safety was assessed in a self-administered standardized questionnaire within 10 days after immunization. YF-specific neutralizing antibody titers were measured 6 months after vaccination in patients receiving corticosteroids. RESULTS: Between July 2008 and February 2011, 102 vaccine recipients completed the safety study (34 receiving corticosteroids and 68 controls). The median age was 54.9 years (interquartile range [IQR] 45.1-60.3 years) and 45 participants had a history of previous YF17D immunization. The median time receiving corticosteroid therapy was 10 months (IQR 1-67 months) and the prednisone or equivalent dosage was 7 mg/day (IQR 5-20). Main indications were autoimmune diseases (n = 14), rheumatoid arthritis (n = 9), and upper respiratory tract infections (n = 8). No serious adverse event was reported; however, patients receiving corticosteroids reported more frequent moderate/severe local reactions than controls (12% and 2%, respectively; relative risk 8.0, 95% confidence interval 1.4-45.9). All subjects receiving corticosteroids who were tested (n = 20) had neutralizing antibody titers >10 after vaccination. CONCLUSION: After YF17D immunization, moderate/severe local reactions may be more frequent in patients receiving systemic corticosteroid therapy. Immunogenicity seems satisfactory. Large-scale studies are needed to confirm these results.
Assuntos
Corticosteroides/administração & dosagem , Vacina contra Febre Amarela/imunologia , Vacina contra Febre Amarela/uso terapêutico , Febre Amarela/imunologia , Febre Amarela/prevenção & controle , Corticosteroides/efeitos adversos , Adulto , Artralgia/induzido quimicamente , Artralgia/imunologia , Estudos de Coortes , Fadiga/induzido quimicamente , Fadiga/imunologia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários , Febre Amarela/epidemiologia , Vacina contra Febre Amarela/efeitos adversos , Vírus da Febre Amarela/imunologiaRESUMO
Little is known about severe imported Plasmodium falciparum malaria in industrialized countries where the disease is not endemic because most studies have been case reports or have included <200 patients. To identify factors independently associated with the severity of P. falciparum, we conducted a retrospective study using surveillance data obtained from 21,888 P. falciparum patients in France during 1996-2003; 832 were classified as having severe malaria. The global case-fatality rate was 0.4% and the rate of severe malaria was ≈3.8%. Factors independently associated with severe imported P. falciparum malaria were older age, European origin, travel to eastern Africa, absence of chemoprophylaxis, initial visit to a general practitioner, time to diagnosis of 4 to 12 days, and diagnosis during the fall-winter season. Pretravel advice should take into account these factors and promote the use of antimalarial chemoprophylaxis for every traveler, with a particular focus on nonimmune travelers and elderly persons.
Assuntos
Malária Falciparum/epidemiologia , Vigilância da População , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , França/epidemiologia , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Viagem , Adulto JovemRESUMO
Trichinellosis is a parasitic zoonosis caused by several species of the viviparous nematode of the genus Trichinella. Trichinellosis is a food borne zoonosis and can be contracted by eating raw or rare meat. This disease can be prevented by domestic and public health measures. France has thus considerably reinforced its system of prevention at slaughterhouses and in 2002 a Trichinella National Reference Centre was implemented. Trichinellosis is considered as a re-emergent disease throughout the world and more than 2500 cases have been reported in France since 1975. The possible severe neurological and cardiovascular complications, the risk of death highlight the need for a better knowledge of the disease and of its impact on public health.
Assuntos
Triquinelose , França , Humanos , Triquinelose/complicações , Triquinelose/terapiaRESUMO
Plasmodium falciparum malaria is a serious health hazard for travelers to malaria-endemic areas and is often diagnosed on return to the country of residence. We conducted a retrospective study of imported falciparum malaria among travelers returning to France from malaria-endemic areas from 1996 through 2003. Epidemiologic, clinical, and parasitologic data were collected by a network of 120 laboratories. Factors associated with fatal malaria were identified by logistic regression analysis. During the study period, 21,888 falciparum malaria cases were reported. There were 96 deaths, for a case-fatality rate of 4.4 per 1,000 cases of falciparum malaria. In multivariate analysis, risk factors independently associated with death from imported malaria were older age, European origin, travel to East Africa, and absence of chemoprophylaxis. Fatal imported malaria remains rare and preventable. Pretravel advice and malaria management should take into account these risk factors, particularly for senior travelers.